

**RECEIVED  
CENTRAL FAX CENTER**

**JAN 17 2005**

Attorney Docket No.: 6544.200-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Persson et al.

Serial No.: 10/669,537

Group Art Unit: 1653

Filed: September 24, 2003

Examiner: Sheridan Snedden

For: Human Coagulation Factor VII Polypeptides

**CERTIFICATE OF FACSIMILE TRANSMISSION  
703-872-9306**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. A Supplemental Amendment (3 pages)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Sheridan Snedden, fax number (703) 872-9306.

Respectfully submitted,

Date: January 17, 2005

  
Csaba Attila Szokolczai  
Novo Nordisk® Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**RECEIVED  
CENTRAL FAX CENTER**

**JAN 17 2005**

Attorney Docket No.: 6544.200-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Persson et al.

Serial No.: 10/669,537

Group Art Unit: 1653

Filed: September 24, 2003

Examiner: Sheridan Snedden

For: Human Coagulation Factor VII Polypeptides

**SUPPLEMENTAL AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed January 10, 2005, please amend the above-captioned application as follows:

**Amendment to THE SPECIFICATION begins on Page 2 of this paper.**

**REMARKS begin on page 3 of this paper.**